Back to News
Market Impact: 0.15
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Source: GlobeNewswire
Healthcare & Biotech
The article states support for Optimi’s planned Phase 2 psilocybin clinical trial in major depressive disorder and Phase 3 MDMA trial in PTSD. The update signals progress toward advancing two psychedelic-based treatment programs, though it provides no financial data, trial timelines, or efficacy results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
OPTH0.35
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Jefferies raises Inovio stock price target on regulatory win
- Humana lifts annual profit forecast as medical costs ease
- Truist raises Vericel stock price target on MACI growth momentum